help button home button Am J Pathol International Conference on Pathology of Chest Diseases
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Körner, M.
Right arrow Articles by Reubi, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Körner, M.
Right arrow Articles by Reubi, J. C.
(American Journal of Pathology. 2005;167:959-968.)
© 2005 American Society for Investigative Pathology

Secretin Receptors in Normal and Diseased Human Pancreas

Marked Reduction of Receptor Binding in Ductal Neoplasia

Meike Körner*, Gregory M. Hayes{dagger}, Ruth Rehmann*, Arthur Zimmermann*, Helmut Friess{ddagger}, Laurence J. Miller{dagger} and Jean Claude Reubi*

From the Division of Cell Biology and Experimental Cancer Research,* Institute of Pathology of the University of Bern, Bern, Switzerland; the Cancer Center,{dagger} Mayo Clinic-Scottsdale, Scottsdale, Arizona; and the Department of Surgery,{ddagger} University of Heidelberg, Heidelberg, Germany

Receptors for gut hormones, which are often overexpressed in cancer, are clinically relevant for receptor-targeted tumor imaging and therapy. Because the receptors for the gut hormone secretin are poorly characterized, we assessed secretin receptor expression in the main secretin target, the human pancreas. We investigated 58 non-neoplastic pancreases and 55 pancreatic tumors for receptor localization and density by in vitro receptor autoradiography using [125I]Tyr10 rat secretin and for secretin receptor mRNA by reverse transcriptase-polymerase chain reaction. Secretin receptors were highly expressed in non-neoplastic ducts and lobuli and also in lower amounts in ductal neoplasias, including ductal adenocarcinoma, intraductal papillary mucinous tumors, and pancreatic intraepithelial neoplasia. Reverse transcriptase-polymerase chain reaction revealed wild-type receptor mRNA in the non-neoplastic pancreas and both wild-type and spliced variant receptor transcripts in ductal adenocarcinomas. Serous cystic tumors were highly positive for secretin receptors, whereas mucinous cystic tumors were negative. This study is the first to describe the precise secretin receptor distribution in human non-neoplastic pancreas and various pancreatic tumors. High secretin receptor expression in the non-neoplastic ducts reflects the major role of secretin in bicarbonate secretion. Reduced secretin binding in pancreatic ductal tumors may relate to (alternatively spliced) secretin receptor isoforms. Thus, secretin receptors in pancreatic tumors may represent potential clinical targets.




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
S. H. Long, M. J. Berna, M. Thill, A. Pace, T. K. Pradhan, K. M. Hoffmann, J. Serrano, and R. T. Jensen
Secretin-Receptor and Secretin-Receptor-Variant Expression in Gastrinomas: Correlation with Clinical and Tumoral Features and Secretin and Calcium Provocative Test Results
J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4394 - 4402.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
I. Nishijima, T. Yamagata, C. M. Spencer, E. J. Weeber, O. Alekseyenko, J. D. Sweatt, M. Y. Momoi, M. Ito, D. L. Armstrong, D. L. Nelson, et al.
Secretin receptor-deficient mice exhibit impaired synaptic plasticity and social behavior
Hum. Mol. Genet., November 1, 2006; 15(21): 3241 - 3250.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Society for Investigative Pathology.